Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted ...

PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a first-in-class ...

The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid ...

(Alliance News) - PureTech Health PLC on Thursday said that the US Food & Drug Administration has granted fast track designation to its antibody LYT-200 for the treatment of acute myeloid leukemia.

BOSTON, January 06, 2025 -- ( BUSINESS WIRE )-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), is pleased to announce that it has appointed UBS as its UK Corporate Broker ...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today ...

PureTech meanwhile is also exploring the use of LYT-100 in other indications, including as a treatment for respiratory complications of long COVID and breast cancer-related, upper limb secondary ...

PureTech Health plc (NASDAQ:PRTC) stock is up on Monday, after the company announced results from ELEVATE IPF Phase 2b trial of deupirfenidone (LYT-100) for idiopathic pulmonary fibrosis (IPF).

Boston-situated clinical-stage biotherapeutics company PureTech’s Phase IIb trial of deupirfenidone met all primary and secondary endpoints, slowing lung degeneration in patients with idiopathic ...

The two doses of deupirfenidone were chosen based on PureTech’s Phase 1 data, which showed that a 550 mg TID dose of deupirfenidone provided approximately equivalent drug exposure to pirfenidone ...

PureTech’s only internal drug program has slowed lung function decline in a phase 2 trial in idiopathic pulmonary fibrosis (IPF). The med, called deupirfenidone, is a deuterated form of Roche ...

LYT-200 is currently being evaluated in two Phase 1/2 trials for the potential treatment of AML/MDS and head and neck cancers PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company” ...